Citations

Clear

941 citation(s) found for "Tan, MH".

Abstract 297: Role of purine metabolism in CLL cell pathobiology and CLL disease progression
McCabe, Chantal E. , O’Brien, Daniel R. , Chen, Yi , Tan, Fenlai , Anthony, Stephen P. , Chen, Yu , Sinha, Sutapa , Han, Weiguo , Wang, Zhiquan , Rabe, Kari G. , Slager, Susan L. , Parikh, Sameer A. , Braggio, Esteban , Dai, Bing, Shen, Yue, Kay, Neil E.

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 297-297

10.1158/1538-7445.am2024-297 Get It

Abstract The treatment of Chronic lymphocytic leukemia (CLL) has been revolutionized in recent years, however CLL is still incurable, and the leukemic cells often develop drug resistance. Previous studies show that the interaction of CLL cells with the bone marrow (BM) microenvironment promotes spontaneous and drug induced survival. But the nature of this interaction is still in need of a full understanding. To pursue this we discerned RNA profiles using RNA-seq in paired CLL cells isolated from untreated blood and BM (n=6) and in untreated patients CLL cells (n=4) cultured alone or cocultured with BM stromal cells (BMSCs). CLL cells from blood/BM and CLL cells cultured alone or with BMSCs were examined by Western blot (WB), untargeted metabolomics (LCMS+GCMS) and preclinical drug sensitivity assays. We found upregulation of 232 genes in CLL cells from BM vs the paired blood and 917 genes in cocultured CLL cells compared to CLL cells cultured alone (p&lt0.05, fold change &gt1.5). Here we detected only 13 genes that overlap between BM and cocultured CLL cells. When we analyzed the expression of these 13 genes in blood CLL cells from a cohort of 162 untreated patients by RNA-seq we found a positive relationship between 4 (PNP, C16orf54, MOB3A, CDK2AP2) with CLL patient clinical outcome including overall survival (OS), progression free survival (PFS), and time to first treatment (TTFT) [multivariable Cox proportional hazards models, p&lt0.05]. Out of the 4 genes, purine nucleoside phosphorylase (PNP), an enzyme in the purine salvage pathway, showed the most significant association for patient’s OS, PFS, and TTFT. Metabolomic profiling indicated an increased level of purine salvage pathway metabolites adenosine, inosine, and hypoxanthine in cocultured CLL cells. WB analysis using blood CLL cells from untreated patients showed a variable PNP protein expression (high, low/no PNP) and induction in PNP protein levels were found in blood CLL cells expressing low/no PNP only when in contact with BM/BMSCs. But PNP inhibitor forodesine did not show any significant killing in high vs low/no PNP group. When we treated CLL cells from untreated patients with Bcl2 inhibitors venetoclax, S55746 and LP-118 (Bcl-2/Bcl-xl inhibitor, Newave), CLL cells showed increasing sensitivity to the Bcl2 inhibitors associated with their PNP expression (high&gtlow&gtno PNP). But a covalent and non-covalent BTKi LP-168 (Newave) cultured with CLL cells showed no difference in drug sensitivity associated with CLL PNP levels. In contrast CLL cells when treated with both venetoclax and LP-168, showed more drug sensitivity in the high PNP expressing CLL cells vs low/no PNP. These results indicate that active purine metabolism in CLL cells can contribute to differential novel agent drug responses of CLL patients. Future studies to understand the exact mechanism of how PNP relates to this differential drug sensitivity should be instructive in regard to alternate maneuvers to treat CLL. Citation Format: Sutapa Sinha, Weiguo Han, Zhiquan Wang, Kari G. Rabe, Susan L. Slager, Chantal E. McCabe, Daniel R. O'Brien, Sameer A. Parikh, Esteban Braggio, Yi Chen, Fenlai Tan, Stephen P. Anthony, Yu Chen, Bing Dai, Yue Shen, Neil E. Kay. Role of purine metabolism in CLL cell pathobiology and CLL disease progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 297.
Long‐term outcomes with abandoning versus extracting sterile leads: A 10‐year population‐based study
Lee, Justin Z. , Talaei, Fahimeh , Sorajja, Dan , Valverde, Arturo M. , Scott, Luis R. , Asirvatham, Samuel J. , Kusumoto, Fred , Mulpuru, Siva K. , Cha, Yong‐Mei , Tan, Min Choon , Valverde, Arturo, Asirvatham, Samuel J , Kusumoto, Fred M , Cha, Yong-Mei , Srivathsan, Komandoor

Mayo Clinic

Pacing and Clinical Electrophysiology | March 16, 2024 | Volume: 47 | Issue: 5 | Pages: 626-634

10.1111/pace.14940 | PMID 38488756 Get It

Abstract Background Long‐term outcomes of sterile lead management strategies of lead abandonment (LA) or transvenous lead extraction (TLE) remain unclear. Methods We performed a retrospective study of a population residing in southeastern Minnesota with follow‐up at the Mayo Clinic and its health systems. Patients who underwent LA or TLE of sterile leads from January 1, 2000, to January 1, 2011, and had follow‐up for at least 10 years or until their death were included. Results A total of 172 patients were included in the study with 153 patients who underwent LA and 19 who underwent TLE for sterile leads. Indications for subsequent lead extraction arose in 9.1% ( n = 14) of patients with initial LA and 5.3% ( n = 1) in patients with initial TLE, after an average of 7 years. Moreover, 28.6% of patients in the LA cohort who required subsequent extraction did not proceed with the extraction, and among those who proceeded, 60% had clinical success and 40% had a clinical failure. Subsequent device upgrades or revisions were performed in 18.3% of patients in the LA group and 31.6% in the TLE group, with no significant differences in procedural challenges (5.2% vs. 5.3%). There was no difference in 10‐year survival probability among the LA group and the TLE group ( p = .64). Conclusion An initial lead abandonment strategy was associated with more complicated subsequent extraction procedures compared to patients with an initial transvenous lead extraction strategy. However, there was no difference in 10‐year survival probability between both lead management approaches.
Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
Kase, Adam M. , Trynda, Justyna , Miller, James L. , Miller, Erin , Petit, Joachim L. , Barrett, Michael T. , Zhou, Yumei , Parent, Ephraim E. , Cai, Hancheng , Knight, Joshua A. , Orme, Jacob J. , Durham, William F., Metz, Thomas , Meurice, Nathalie , Edenfield, Brandy , Demirer, Aylin Alasonyalılar , Hickman, Peyton G. , Pawlush, Matthew L. , Wickland, Daniel P. , Tan, Winston , Copland, John A. , Gleba, Justyna , Petit, Joachim L , Orme, Jacob J , Reynolds, Jordan P , Durham, William F , Metz, Thomas M , Meurice, Nathalie , Edenfield, Brandy , Alasonyalilar Demirer, Aylin , Bilgili, Ahmet , Hickman, Peyton G , Pawlush, Matthew L , Marlow, Laura , Wickland, Daniel P , Tan, Winston , Copland, John A , Knight, Joshua A , Parent, Ephraim E , Cai, Hancheng , Reynolds, Jordan , Bilgili, Ahmet , Marlow, Laura A.

Mayo Clinic

Molecular Cancer Therapeutics | March 5, 2024 | Volume: 23 | Issue: 6 | Pages: 823-835

10.1158/1535-7163.mct-23-0296 | PMID 38442920 Get It

Abstract Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive malignancy with poor outcomes. To investigate novel therapeutic strategies, we characterized three new metastatic prostate cancer patient derived-tumor xenograft (PDTX) models and developed 3D spheroids from each to investigate molecular targeted therapy combinations including CDK4/6 inhibitors (CDK4/6i) with AKT inhibitors (ATKi). Metastatic prostate cancer tissue was collected and three PDTX models were established and characterized using whole-exome sequencing. PDTX 3D spheroids were developed from these three PDTXs to show resistance patterns and test novel molecular-targeted therapies. CDK4/6i's were combined with AKTi's to assess synergistic antitumor response to prove our hypothesis that blockade of AKT overcomes drug resistance to CDK4/6i. This combination was evaluated in PDTX three-dimensional (3D) spheroids and in vivo experiments with responses measured by tumor volumes, PSA, and Ga-68 PSMA-11 PET-CT imaging. We demonstrated CDK4/6i's with AKTi's possess synergistic antitumor activity in three mCRPC PDTX models. These models have multiple unique pathogenic and deleterious genomic alterations with resistance to single-agent CDK4/6i's. Despite this, combination therapy with AKTi's was able to overcome resistance mechanisms. The IHC and Western blot analysis confirmed on target effects, whereas tumor volume, serum PSA ELISA, and radionuclide imaging demonstrated response to therapy with statistically significant SUV differences seen with Ga-68 PSMA-11 PET-CT. These preclinical data demonstrating antitumor synergy by overcoming single-agent CDK 4/6i as well as AKTi drug resistance provide the rational for a clinical trial combining a CDK4/6i with an AKTi in patients with mCRPC whose tumor expresses wild-type retinoblastoma 1.
Characteristics of and risk factors for COVID-19 breakthrough infections in idiopathic inflammatory myopathies: results from the COVAD study
Ravichandran, Naveen , Day, Jessica , Nune, Arvind , Nikiphorou, Elena , Tan, Ai Lyn , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Kuwana, Masataka , Patel, Aarat , Wincup, Chris , Tehozol, Erick Adrian Zamora , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akarawatcharangura , Kibbi, Lina El , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Chinoy, Hector , Gupta, Latika, Group, COVAD Study, Ranjan, Rajiv , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , M, Manesh Manoj, Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Gaur, Prithvi Sanjeevkumar , Mamadapur, Mahabaleshwar , Ghodke, Akanksha, Kadam, Esha , Fazal, Zoha Zahid , Kardeş, Sinan , Yıldırım, Reşit, Maurier, F. , Meyer, Alain, Atzeni, Fabiola , Bocci, Elena Bartoloni, Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Grignaschi, Silvia, Giollo, Alessandro, Lini, Daniele , Alluno, Alessia, Loarce‐Martos, Jesus , Aránega, Raquel, Nakashima, Ran , Sato, Shinji , Kaneko, Yuko , Gono, Takahisa, Tomaras, Stylianos , Aharonov, Mr Or, Nagy‐Vincze, Melinda , Schrieber, Karen, bouchti, Pr Imane El, Baba, Zineb, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Ouma Devi , Palalane, Elisa, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane, Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Harifi, Ghita, Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Argueta, Sandra, Quijivix, Daniel, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, M, Roberto Morales Idania Escalante, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Agarwal, Vikas , Giollo, Alessandro , Gupta, Latika , Naveen, R , Day, Jessica , Nune, Arvind , Tan, Ai Lyn , Ziade, Nelly , Milchert, Marcin , Parodis, Ioannis , Gracia-Ramos, Abraham Edgar , Kuwana, Masataka , Knitza, Johannes , Pauling, John D , Wincup, Chris , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Lilleker, James B , Gheita, Tamer , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Agarwal, Vikas , Velikova, Tsvetelina , Zamora Tehozol, Erick Adrian , Dey, Dzifa , Caballero-Uribe, Carlo Vinicio , De Angelis, Rossella , Hoff, Leonardo Santos , Sen, Parikshit , Joshi, Mrudula , Saha, Sreoshy , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Jagtap, Kshitij , Gracia‐Ramos, Abraham Edgar , Cavagna, Lorenzo , Chen, Yi‐Ming , Makol, Ashima , Agarwal, Vishwesh , Pauling, John D , Barman, Bhupen , Rojas Serrano, Jorge , Torre, Ignacio García‐De La , Colunga-Pedraza, I. J. , Goo, Phonpen Akawatcharangura , Shumnalieva, Russka , Halabi, Hussein , Gheita, Tamer A. , Chatterjee, Tulika , Distler, Oliver , Saavedra, Miguel A , Aggarwal, Rohit , Group, COVAD Study, Singh, Yogesh Preet , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Giannini, Margherita , Campagne, Julien , Meyer, Alain , Papa, Nicoletta Del , Sambataro, Gianluca , Govoni, Marcello , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Venerito, Vincenzo , Andréoli, Laura , Iannone, Florenzo , Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Prieto‐González, Sergio , Yoshida, Akira , Kimura, Naoki, Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Griger, Zoltán , Hmamouchi, Ihsane , Emorinken, Airenakho , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Landon‐Cardinal, Océane , Arbeláez-Cortés, Álvaro , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , So, Ho , Ugarte‐Gil, Manuel F. , Fathi, Hanan Mohamed , Mohammed, Reem Hamdy A , Harifi, Ghita , Salinas, Rodrigo Nicolás Garcia

Mayo Clinic

Rheumatology | March 2, 2024 | Volume: 64 | Issue: 2 | Pages: 597-606

10.1093/rheumatology/keae128 | PMID 38430474 Get It

Abstract Objectives The objective of this study was to explore the prevalence, characteristics and risk factors of COVID-19 breakthrough infections (BIs) in idiopathic inflammatory myopathies (IIMs) using data from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods A validated patient self-reporting e-survey was circulated by the COVAD study group to collect data on COVID-19 infection and vaccination in 2022. BIs were defined as COVID-19 occurring ≥14 days after two vaccine doses. We compared BI characteristics and severity among patients with IIMs, patients with other autoimmune rheumatic and non-rheumatic diseases (AIRD, nrAID), and healthy controls (HCs). Multivariable Cox regression models were used to assess the risk factors for BI, severe BI ,and hospitalizations among patients with IIMs. Results Among the 9449 included responses, BIs occurred in 1447 respondents (15.3%). The median age was 44 years [interquartile range (IQR) 21], 77.4% were female, and 182 BIs (12.9%) occurred among the 1406 patients with IIMs. Multivariable Cox regression among the data for patients with IIMs showed increasing age to be a protective factor for BIs [hazard ratio (HR) = 0.98, 95% CI = 0.97–0.99], and HCQ and SSZ use were risk factors (HR = 1.81, 95% CI = 1.24–2.64, and HR = 3.79, 95% CI = 1.69–8.42, respectively). Glucocorticoid use was a risk factor for a severe BI (HR = 3.61, 95% CI = 1.09–11.8). Non-white ethnicity (HR = 2.61, 95% CI = 1.03–6.59) was a risk factor for hospitalization. Compared with other groups, patients with IIMs required more supplemental oxygen therapy (IIMs = 6.0% vs AIRDs = 1.8%, nrAIDs = 2.2% and HCs = 0.9%), intensive care unit admission (IIMs = 2.2% vs AIRDs = 0.6%, nrAIDs and HCs = 0%), advanced treatment with antiviral or monoclonal antibodies (IIMs = 34.1% vs AIRDs = 25.8%, nrAIDs = 14.6% and HCs = 12.8%) and had more hospitalization (IIMs = 7.7% vs AIRDs = 4.6%, nrAIDs = 1.1% and HCs = 1.5%). Conclusion Patients with IIMs are susceptible to severe COVID-19 BIs. Age and immunosuppressive treatments were related to the risk of BIs.
Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey
Yoshida, Akira , Maroufy, Vahed , Kuwana, Masataka , Shaharir, Syahrul Sazliyana , Kadam, Esha , Goo, Phonpen Akawatcharangura , Milchert, Marcin , Dey, Dzifa , Velikova, Tsvetelina , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Ziadé, Nelly , Kibbi, Lina El, Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Kardeş, Sinan , Vince, Melinda Nagy, Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal, Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Vaidya, Binit , Yıldırım, Reşit, Atzeni, Fabiola , Bocci, Elena Bartoloni, Orsolini, Giovanni , Angelis, Rossella De , Giollo, Alessandro, Fornaro, Marco, González, Raquel , Nakashima, Ran , Sato, Shinji , Kimura, Naoki , Kaneko, Yuko , Gono, Takahisa , Tomaras, Stylianos, Aharonov, Or, Bouchti, I. El , Baba, Zineb, Maurier, F. , Meyer, Alain, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Harifi, Ghita, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, Nunez, Lilith Stange, Vergara, Cristián, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Mendoza, Idania Escalante, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Patel, Aarat , Tehozol, Erick Adrian Zamora , Chalico, Javier Merayo, Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Hasan, A T M Tanveer , Salim, Babur , Gupta, Latika , Kuwana, Masataka , Lilleker, James B , Day, Jessica , Milchert, Marcin , Dey, Dzifa , Gracia-Ramos, Abraham Edgar , Parodis, Ioannis , Tan, Ai Lyn , Nune, Arvind , Ziade, Nelly , Knitza, Johannes , Distler, Oliver , Chinoy, Hector , Aggarwal, Rohit , Gupta, Latika , Agarwal, Vikas , Velikova, Tsvetelina , Zamora Tehozol, Erick Adrian , Caballero-Uribe, Carlo Vinicio , Yoshida, Akira , De Angelis, Rossella , Li, Yuan , Makol, Ashima , Sen, Parikshit , Agarwal, Vishwesh , Day, Jessica , Chen, Yi‐Ming , Saha, Sreoshy , Gracia‐Ramos, Abraham Edgar , Nune, Arvind , Cavagna, Lorenzo , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study, Griger, Zoltán , Singh, Yogesh Preet , Ranjan, Rajiv , Jain, Avinash , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Ajmani, Sajal , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Sambataro, Gianluca , Govoni, Marcello , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Danieli, Maria Giovanna , Venerito, Vincenzo , Grignaschi, Silvia , Giollo, Alessandro, Alunno, Alessia , Iannone, Florenzo , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Loarce‐Martos, Jesus , Prieto‐González, Sergio , Gonzalez, Raquel Aranega, Tomaras, Stylianos , Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Baba, Zineb, Giannini, Margherita , Campagne, Julien , Meyer, Alain , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Arbeláez-Cortés, Álvaro , Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Doskaliuk, Bohdana , Emorinken, Airenakho , Olaosebikan, Hakeem , Ugarte‐Gil, Manuel F. , Mohammed, Reem Hamdy A , Harifi, Ghita , Fuentes-Silva, Yurilís , Salinas, Rodrigo Nicolás Garcia , Andréoli, Laura , Lini, Daniele , Schreiber, Karen , Pauling, John D , Wincup, Chris , Barman, Bhupen , Rojas Serrano, Jorge , Torre, Ignacio García-De La, Colunga-Pedraza, I. J. , Shumnalieva, Russka , Hoff, Leonardo Santos , Halabi, Hussein , Gheita, Tamer A. , Chatterjee, Tulika

Mayo Clinic

Rheumatology Advances in Practice | February 29, 2024 | Volume: 8 | Issue: 2 | Pages: No page available

10.1093/rap/rkae028 | PMID 38524696 Get It

Abstract Objectives To investigate health-related quality of life in patients with idiopathic inflammatory myopathies (IIMs) compared with those with non-IIM autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs) and without autoimmune diseases (controls) using Patient-Reported Outcome Measurement Information System (PROMIS) instrument data obtained from the second COVID-19 vaccination in autoimmune disease (COVAD-2) e-survey database. Methods Demographics, diagnosis, comorbidities, disease activity, treatments and PROMIS instrument data were analysed. Primary outcomes were PROMIS Global Physical Health (GPH) and Global Mental Health (GMH) scores. Factors affecting GPH and GMH scores in IIMs were identified using multivariable regression analysis. Results We analysed responses from 1582 IIM, 4700 non-IIM AIRD and 545 nrAID patients and 3675 controls gathered through 23 May 2022. The median GPH scores were the lowest in IIM and non-IIM AIRD patients {13 [interquartile range (IQR) 10–15] IIMs vs 13 [11–15] non-IIM AIRDs vs 15 [13–17] nrAIDs vs 17 [15–18] controls, P < 0.001}. The median GMH scores in IIM patients were also significantly lower compared with those without autoimmune diseases [13 (IQR 10–15) IIMs vs 15 (13–17) controls, P < 0.001]. Inclusion body myositis, comorbidities, active disease and glucocorticoid use were the determinants of lower GPH scores, whereas overlap myositis, interstitial lung disease, depression, active disease, lower PROMIS Physical Function 10a and higher PROMIS Fatigue 4a scores were associated with lower GMH scores in IIM patients. Conclusion Both physical and mental health are significantly impaired in IIM patients, particularly in those with comorbidities and increased fatigue, emphasizing the importance of patient-reported experiences and optimized multidisciplinary care to enhance well-being in people with IIMs.
Incidence and clinical outcomes of perforations during mechanical thrombectomy for medium vessel occlusion in acute ischemic stroke: A retrospective, multicenter, and multinational study
Musmar, Basel , Salim, Hamza , Kobeissi, Hassan , Shaikh, Hamza , Khalife, Jane , Abdalkader, Mohamad , Klein, Piers , Heit, Jeremy J. , Regenhardt, Robert W. , Cancelliere, Nicole M , Amllay, Abdelaziz , Dusart, Anne , Bellante, Flavio, Rouchaud, Aymeric , Puri, Ajit S , Dyzmann, Christian , Kan, Peter , Colasurdo, Marco , Berge, Jérôme , Barreau, Xavier , Nedelcu, Simona , Henninger, Nils , Marotta, Thomas R. , Stapleton, Christopher J. , Rabinov, James D. , Dofuku, Shogo , Tan, Benjamin Yong‐Qiang , Salazar‐Marioni, Sergio , Capirossi, Carolina , Chervak, Lina , Adeeb, Nimer , Tjoumakaris, Stavropoula , Khandelwal, Priyank , Biswas, Arundhati , Clarençon, Frédéric , Elhorany, Mahmoud , Premat, Kévin , Valente, Iacopo , Filipe, João Pedro , Varela, Ricardo , Quintero‐Consuegra, Miguel , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Yedavalli, Vivek , Aziz, Yasmin , Stracke, Christian Paul , Kadirvel, Ramanathan , Hsieh, Cheng‐Yang , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Musmar, Basel , Salim, Hamza , Kobeissi, Hassan , Klein, Piers , Nguyen, Thanh N , Regenhardt, Robert W , Bellante, Flavio , Forestier, Géraud , Marnat, Gaultier , Ota, Takahiro , Dofuku, Shogo , Yeo, Leonard Ll , Salazar-Marioni, Sergio , Jabbour, Pascal , Gonzalez, Nestor R , Möhlenbruch, Markus A , Jesser, Jessica , Aziz, Yasmin , Alexandru Radu, Răzvan , Faizy, Tobias D , Fahed, Robert , Liebeskind, David S. , Heit, Jeremy J , Yedavalli, Vivek S , Cancelliere, Nicole M , Rouchaud, Aymeric , Colasurdo, Marco , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Varela, Ricardo , Dmytriw, Adam A. , Ghozy, Sherief , Siegler, James E. , Nguyen, Thanh N. , Bernstock, Joshua D. , Naamani, Kareem El , Meyer, Lukas , Forestier, Géraud , Saleme, Suzana , Mounayer, Charbel , Fiehler, Jens , Kühn, Anna Luisa , Sibon, Igor , Gopinathan, Anil , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Renieri, Leonardo , Mowla, Ashkan , Vagal, Achala , Cuellar, Hugo , Jabbour, Pascal , Khandelwal, Priyank , Pedicelli, Alessandro , Schiphorst, Adrien ter , Harker, Pablo , Gory, Benjamin , Hecker, Constantin , Killer-Oberpfalzer, Monika , Griessenauer, Christoph J. , Thomas, Ajith J , Radu, Răzvan Alexandru , Fahed, Robert , Weyland, Charlotte S. , Mendes Pereira, Vitor

Mayo Clinic

European Stroke Journal | February 27, 2024 | Volume: 9 | Issue: 2 | Pages: 328-337

10.1177/23969873231219412 | PMID 38409796 Get It

Abstract Background: Mechanical thrombectomy (MT) has revolutionized the treatment of acute ischemic stroke (AIS) due to large vessel occlusion (LVO), but its efficacy and safety in medium vessel occlusion (MeVO) remain less explored. This multicenter, retrospective study aims to investigate the incidence and clinical outcomes of vessel perforations (confirmed by extravasation during an angiographic series) during MT for AIS caused by MeVO. Methods: Data were collected from 37 academic centers across North America, Asia, and Europe between September 2017 and July 2021. A total of 1373 AIS patients with MeVO underwent MT. Baseline characteristics, procedural details, and clinical outcomes were analyzed. Results: The incidence of vessel perforation was 4.8% (66/1373). Notably, our analysis indicates variations in perforation rates across different arterial segments: 8.9% in M3 segments, 4.3% in M2 segments, and 8.3% in A2 segments (p = 0.612). Patients with perforation had significantly worse outcomes, with lower rates of favorable angiographic outcomes (TICI 2c-3: 23% vs 58.9%, p < 0.001; TICI 2b-3: 56.5% vs 88.3%, p < 0.001). Functional outcomes were also worse in the perforation group (mRS 0–1 at 3 months: 22.7% vs 36.6%, p = 0.031; mRS 0–2 at 3 months: 28.8% vs 53.9%, p < 0.001). Mortality was higher in the perforation group (30.3% vs 16.8%, p = 0.008). Conclusion: This study reveals that while the occurrence of vessel perforation in MT for AIS due to MeVO is relatively rare, it is associated with poor functional outcomes and higher mortality. The findings highlight the need for increased caution and specialized training in performing MT for MeVO. Further prospective research is required for risk mitigation strategies.
Comparing Cochlear Implant Outcomes in 100 Patients with Sporadic Vestibular Schwannoma Managed with Observation, Radiosurgery, or Microsurgery: A Multi-Institutional Review
Dornhoffer, James R. , Marinelli, John P. , Lohse, Christine M. , McMenomey, Sean O., Brown, Kevin D. , Lucas, Jacob C. , Babu, Seilesh C. , Lindquist, Nathan R. , Harvey, Erin M. , Deep, Nicholas L. , Cerasiello, Samantha Y., Kircher, Matthew L., Espahbodi, Mana , Tooker, Evan L., Lloyd, Simon , Carlson, Matthew L. , Cottrell, Justin , Roland, J. Thomas , Thompson, Nicholas J. , Perkins, Elizabeth L. , Rahne, Torsten , Plontke, Stefan K. , Tan, Donald , Hunter, Jacob B. , Harvey, Erin

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1779955 Get It

Defining signals that promote human alveolar type I differentiation
Li, Yong , Prakash, Y. S. , Tan, Qi , Tschumperlin, Daniel J. , Prakash, Y S , Tschumperlin, Daniel J

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | February 13, 2024 | Volume: 326 | Issue: 4 | Pages: L409-L418

10.1152/ajplung.00191.2023 | PMID 38349124 Get It

Alveolar type I (ATI) epithelial cells perform essential roles in maintaining lung function but have been challenging to study. We explored the signals that promote ATI fate in 3-D organoid cultures generated from either mixed distal human lung cells or purified alveolar type II (ATII) cells. This work fills an important void in our experimental repertoire for studying alveolar epithelial cells and identifies signals that promote human ATII to ATI cell differentiation.
Effect of age on in‐hospital outcomes of transvenous lead extraction for infected cardiac implantable electronic device
Tan, Min Choon , Ang, Qi Xuan , Yeo, Yong Hao , Thong, Jia Yean, Tolat, Aneesh , Scott, Luis R. , Lee, Justin Z. , Yeo, Yong Hao , Tan, Min C

Mayo Clinic

Pacing and Clinical Electrophysiology | February 7, 2024 | Volume: 47 | Issue: 4 | Pages: 577-582

10.1111/pace.14939 | PMID 38319639 Get It

AbstractBackgroundThe real‐world data on the safety profile of transvenous lead extraction (TLE) for infected cardiac implantable electronic devices (CIED) among elderly patients is not well‐established. This study aimed to evaluate the hospital outcomes between patients of different age groups who underwent TLE for infected CIED.MethodUsing the Nationwide Readmissions Database, our study included patients aged ≥18 years who underwent TLE for infected CIED between 2017 and 2020. We divided the patients into four groups: Group A. Young (<50 years), Group B. Young intermediate (50–69 years old), Group C. Older intermediate (70–79 years old), and Group D. Octogenarian (≥80 years old). We then analyzed the in‐hospital outcome and 30‐day readmission between these age groups.ResultsA total of 10,928 patients who were admitted for TLE of infected CIED were included in this study: 982 (9.0%) patients in group A, 4,234 (38.7%) patients in group B, 3,204 (29.3%) patients in group C and 2,508 (23.0%) of patients in group D. Our study demonstrated that the risk of early mortality increased with older age (Group B vs. Group A: OR: 1.92, 95% CI: 1.19‐3.09, p < .01; Group C vs. Group A: OR: 2.47, 95% CI: 1.51‐4.04, p < .01; Group D vs. Group A: OR: 2.82, 95% CI: 1.69‐4.72, p < .01). The risk of non‐home discharge also increased in elderly groups (Group B vs. Group A: OR: 1.89; 95% CI: 1.52‐2.36; p < .01; Group C vs. Group A: OR: 2.82; 95% CI 2.24‐3.56; p < .01; Group D vs. Group A: OR: 4.16; 95% CI: 3.28‐5.28; p < .01). There was no significant difference in hospitalization length and 30‐day readmission between different age groups. Apart from a higher rate of open heart surgery in group A, the procedural complications were comparable between these age groups.ConclusionElderly patients had worse in‐hospital outcomes in early mortality and non‐home discharge following the TLE for infected CIED. There was no significant difference between elderly and non‐elderly groups in prolonged hospital stay and 30‐day readmission. Elderly patients did not have a higher risk of procedural complications.
Impact of age on hospital outcomes after catheter ablation for ventricular tachycardia
Tan, Min Choon , Yeo, Yong Hao , Ang, Qi Xuan , Kiwan, Chrystina, Fatunde, Olubadewa A. , Lee, Justin Z. , Tolat, Aneesh , Sorajja, Dan , Fatunde, Olubadewa, Yeo, Yong Hao , Tan, Min C

Mayo Clinic

Journal of Arrhythmia | February 7, 2024 | Volume: 40 | Issue: 2 | Pages: 317-324

10.1002/joa3.12998 | PMID 38586842 Get It

AbstractBackgroundThe real‐world data on the safety profile of ventricular tachycardia (VT) ablation among elderly patients is not well‐established. This study aimed to evaluate the procedural outcomes among those aged 18–64 years versus those aged ≥65 years who underwent catheter ablation of VT.MethodUsing the Nationwide Readmissions Database, our study included patients aged ≥18 years who underwent VT catheter ablation between 2017 and 2020. We divided the patients into non‐elderly (18–64 years old) and elderly age groups (≥65 years old). We then analyzed the in‐hospital procedural outcome and 30‐day readmission between these two groups.ResultsOur study included 2075 (49.1%) non‐elderly patients and 2153 (50.9%) elderly patients who underwent VT ablation. Post‐procedurally, elderly patients had significantly higher rates of prolonged index hospitalization (≥7 days; 35.5% vs. 29.3%, p < .01), non‐home discharge (13.4% vs. 6.0%, p < .01), 30‐day readmission (17.0% vs. 11.4%, p < .01), and early mortality (5.5% vs. 2.4%, p < .01). There was no significant difference in the procedural complications between two groups, namely vascular complications, hemopericardium/cardiac tamponade, cerebrovascular accident (CVA), major bleeding requiring blood transfusion, and systemic embolization. Through multivariable analysis, the elderly group was associated with higher odds of early mortality (OR: 7.50; CI 1.86–30.31, p = .01), non‐home discharge (OR: 2.41; CI: 1.93–3.00, p < .01) and 30‐day readmission (OR: 1.58; CI 1.32–1.89, p < .01).ConclusionElderly patients have worse in‐hospital outcome, early mortality, non‐home discharge, and 30‐day readmission following catheter ablation for VT. There was no significant difference between elderly and non‐elderly groups in the procedural complications.